



(51) International Patent Classification:

C07D 307/60 (2006.01) *C07C 59/74* (2006.01)
C07B 53/00 (2006.01) *C12N 9/10* (2006.01)
C07C 229/04 (2006.01)

(21) International Application Number:

PCT/IB2014/060140

(22) International Filing Date:

25 March 2014 (25.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/805,786 27 March 2013 (27.03.2013) US

(71) Applicant: PFIZER IRELAND PHARMACEUTICALS
[IE/IE]; Operations Support Group, Ringaskiddy, County
Cork (IE).(72) Inventors: DEBARGE, Sebastien; c/o Pfizer Manufactur-
ing Ireland, Operations Support Group, Ringaskiddy,
County Cork (IE). ERDMAN, David Thomas; c/o Pfizer
Inc., Portage Road, Kalamazoo, Michigan 49001 (US).
O'NEILL, Padraig Mary; c/o Pfizer Manufacturing Ire-
land, Operations Support Group, Ringaskiddy, County
Cork (IE). KUMAR, Rajesh; c/o Pfizer Worldwide Re-
search and Development, Eastern Point Road, Groton,
Connecticut 06340 (US). KARMILOWICZ, Michael
John; c/o Pfizer Worldwide Research and Development,
Eastern Point Road, Groton, Connecticut 06340 (US).(74) Agent: LANE, Graham; Pfizer Limited, Ramsgate Road,
Sandwich Kent CT13 9NJ (GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
 ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN



(57) Abstract: The invention provides processes for the manufacture of a compound of formula (I^A). The invention further provides improved methods for the conversion of the compound of formula (I^A) into pregabalin.